

## DAFTAR PUSTAKA

- Asadullah K., Sterry W., Volk H. D. 2003. Interleukin-10 therapy – review of a new approach. *Pharmacol Rev.* 55:241-69.
- Balkwill F., Mantovani A. 2001. Inflammation and cancer: back to Virchow?. *Lancet.* 357: 539-45.
- Barrat F. J., et al. 2002. *In vitro* generation of interleukin 10-producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. *J. Exp. Med.* 195, 603–616.
- Blomhoff R., & Blomhoff H. K. 2006. Overview of retinoid metabolism and function. *J. Neurobiol.* 66, 606–630.
- Bourreille A., Segain J. P., Raingeard de la Bletiere D., Siavoshian S., Valette G., Galmiche J. P., and Blottiere H. M. 1999. Lack of IL-10 regulation of antigen presentation-associated molecules expressed on colonic epithelial cells. *Eur J Clin Investig.* 29: 48–55.
- Boonstra A., et al. 2006. Macrophages and myeloid DC, but not plasmacytoid DC, produce IL-10 in response to MyD88- and TRIF- dependent TLR signals, and TLR-independent signals. *J. Immunol.* 177, 7551–7558.
- Carson W.E., Lindemann M. J., Baiocchi R., Linett M., Tan J. C., Chou C. C., Narula S., and Caligiuri M. A. 1995. The functional characterization of interleukin-10 receptor expression on human natural killer cells. *Blood.* 85: 3577–85.
- Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A. 2009. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. *Carcinogenesis* 30: 1073-1081.
- Dawson H. D. et al. 2006. Direct and indirect effects of retinoic acid on human Th2 cytokine and chemokine expression by human T lymphocytes. *BMC Immunol.* 7, 27.
- Dillon S., et al. 2004. A Toll-like receptor 2 ligand stimulates Th2 responses *in vivo*, via induction of extracellular signal-regulated kinase

- mitogen-activated protein kinase and c-Fos in dendritic cells. *J. Immunol.* **172**, 4733–4743.
- Drake R.L., Vogi W., Mitchell A.W.M. 2007. Grays Anatomy. 2<sup>nd</sup> ed. China: Elsevier Churchill Livingstone p. 279.
- Eaden J. A., Abrams K. R., Mayberry J. F. 2001. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. *Gut* 48: 526-535.
- Franke A., et al. 2008. Sequence variants in *IL10*, *ARPC2* and multiple other loci contribute to ulcerative colitis susceptibility. *Nature Genet.* **40**, 1319–1323.
- Fiorentino D. F., Zlotnik A., Mosmann T. R., Howard M., and O'Garra A. 1991. IL-10 inhibits cytokine production by activated macrophages. *J Immunol.* 147: 3815-22.
- Gartner L.P., Hiatt J.L. 2007. *Color Textbook of Histology*. 3<sup>th</sup> ed. Philadelphia : W.B Saunders Company. 398-409.
- Gillen C.D., et al. 1994. Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. *Gut*, 35, 1590-1592.
- Gommeaux J., Cano C., Garcia S., Gironella M., Pieri S., Culcasi M. et al. 2007. Colitis and colitis-assosiated cancer are exacerbated in mice deficient for tumor protein 53-induced nuclear protein 1. *Mol. Cell. Biol.* 27(6): 2215-28.
- Hana Ratnawati, Khie Khiong, Sylvia Soeng, Sri Utami Sugeng, Evan Kristiono, Shella Hudaya. 2008. Pengaruh ekstrak Buah Merah (*Pandanus conoideus* Lam.) terhadap berat limpa, jumlah dan proliferasi limfosit pada mencit jantan galur Swiss-webster yang diinokulasi *Listeria monocytogenes*. Disampaikan dalam KONAS XII dan PIN PAAI (Perhimpunan Ahli Anatomi Indonesia) Jakarta, 20-21 Juni.
- Hanahan D., Weinberg R.A. 2000. The Hallmarks of cancer. *Cell*. 100: 57-70.
- Hawrylowicz C. M., O'Garra, A. 2005. Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. *Nature Rev. Immunol.* **5**, 271–283.
- I Made Budi. 2005. Seri Agrisehat Buah Merah. Jakarta: Penebar Swadaya. 17-23.
- Iwasaki A., Kelsall B. L. 2001. Unique functions of CD11b+, CD8α+, and double-negative Peyer's patch dendritic cells. *J. Immunol.* **166**, 4884–4890.
- Iwasaki A. 2007. Mucosal dendritic cells. *Annu. Rev.Immunol.* 25: 381–418 .

- Iwasaki A., Kelsall B. L. 2001. Unique functions of CD11b+, CD8α+, and double-negative Peyer's patch dendritic cells. *J. Immunol.* 166: 4884–90.
- Izcue A., Coombes J. L., Powrie F. 2009. Regulatory lymphocytes and intestinal inflammation. *Annu. Rev. Immunol.* 27, 313–338.
- Jemal A., Siegel R., Ward E., Murray T., Xu J., Thu M.J. 2007 Cancer statistics, CA cancer J Clin. 57:43-66
- Kang S. S., Allen P. M. 2005. Priming in the presence of IL-10 results in direct enhancement of CD8+ T cell primary responses and inhibition of secondary responses *J. Immunol.* 174: 5382-9.
- Karin M., 2008. The NF-κB kinase-a bridge between inflammation and cancer. *Cell research.* 18:334-342.
- Karin M., Greten F.R. 2005. NF-κB linking inflammation and immunity to cancer development and progression. *Nature Rev Immunol.* 5: 749-759.
- Kaiser F. et al. 2009. TPL-2 negatively regulates interferon- $\beta$  production in macrophages and myeloid dendritic cells. *J. Exp. Med.* 206, 1863–1871.
- Kemas Ali Hanafiah. 2005. Rancangan Percobaan Aplikatif: aplikasi kondisional bidang pertanian, perternakan, perikanan, industri, dan hayati. Jakarta: PT Raja Grafindo Persada. p10-12.
- Kim S. et al. 2009. Carcinoma-produced factors activate myeloid cells trough TLR2 to stimulate metatasis. *Nature* 457, 102-106.
- Kobayashi M., et al. 2003. Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. *J. Clin. Invest.* 111: 1297–308.
- Kucharzik T., Luger N., Pauels H. G., Domschke W., and Stoll R. 1995. IL-4, IL-10 and IL-13 down-regulate monocyte-chemoattracting protein-1 (MCP-1) production in activated intestinal epithelial cells. *Clin. Exp. Immunol.* 111: 152-157.
- Kuhn R., Lohler J., Rennick D., Rajewsky K., and Muller W. 1993. Interleukin-10-deficient mice develop chronic enterocolitis. *Cell.* 75: 263-74.
- Kundu J. K., Surh Y. J. 2008. Inflammation: gearing the journey to cancer. *Mutat Res* 659: 15-30.

- Lewin K. J., Riddell R. H., and Weinstein W. M. 1992. Inflammatory bowel diseases. In: *Gastrointestinal Pathology and Its Clinical Implications*, KJ Lewin, RH Riddell, and WM Weinstein (eds). Igaku-Shoin, New York, pp. 812-989.
- Lin W. W., Karin M. 2007. A cytokine-mediated link between innate immunity, inflammation and cancer. *JCI*. 117(5):1175-83.
- Mathurin P., Xiong S., Kharbanda K. K., Veal N., Miyahara T., Motomura K., Ripper R. A., Bachem M. G., and Tsukamoto H. 2002. IL-10 receptor and coreceptor expression in quiescent and activated stellate cells. *Am J Physiol Gastrointest Liver Physiol*. 282: 981-90.
- Mantovani A. 2009. Cancer-related inflammation: the seventh hallmark of cancer. *American Society of Clinical Oncology*. 723-726.
- Maynard C. L. *et al.* 2007. Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3- precursor cells in the absence of interleukin 10. *Nature Immunol*. 8, 931-941.
- Maynard C. L., Weaver C. T. 2008. Diversity in the contribution of interleukin-10 to T-cell-mediated immune regulation. *Immunol. Rev.* 226, 219–233 .
- Medzhitov R. 2007. Recognition of microorganisms and activation of the immune response. *Nature* 449, 819–826.
- Medzhitov R. 2008. Origin and physiological roles of inflammation. *Nature*, 454, 428-435.
- Moore K. W., de Waal Malefy R., Coffman R. L., O'Garra A. 2001. Interleukin-10 and the interleukin-10 receptor *Annu. Rev. Immunol.* 19: 683-765.
- Mora J. R., *et al.* 2006. Generation of gut-homing IgAsecreting B cells by intestinal dendritic cells. *Science* 314, 1157–1160.
- Murray P. J. 2006. Understanding and exploiting the endogenous interleukin-10/STAT3-mediated antiinflammatory response. *Curr. Opin. Pharmacol.* 6, 379–386.
- Mucida D., *et al.* 2007. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. *Science* 317, 256–260.

- O'Garra A., Barrat F. J., Castro A. G., Vicari A., Hawrylowicz C. 2008. Strategies for use of IL-10 or its antagonists in human disease. *Immunol. Rev.* **223**, 114–131.
- O'Garra A. & Vieira P. 2004. Regulatory T cells and mechanisms of immune system control. *Nature Med.* **10**, 801–805.
- Riddell R. H. 1995. Pathology of idiopathic inflammatory bowel disease. In: *Inflammatory Bowel Disease*, JB Kirsner and RG Shorter (eds). Williams & Wilkins, Baltimore, Maryland, pp. 517-552.
- Roncarolo M. G. *et al.* 2006. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. *Immunol. Rev.* **212**, 28–50.
- Rosenberg D., Giardina C., Tanaka T. 2009. Mouse models for study of colon carcinogenesis. *Carcinogenesis*. 30(2): 183-96.
- Saraiva M., *et al.* 2009. Interleukin-10 production by Th1 cells requires interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose. *Immunity* **31**, 209–219.
- Saraiva M. & O'Garra A. 2010. The Regulation of IL-10 production by immune cells. *Nature Med.* **10**, 170-181.
- Smith P. D., Ochsenbauer-Jambor, C. & Smythies, L. E. 2005. Intestinal macrophages: unique effector cells of the innate immune system. *Immunol. Rev.* **206**: 149–59.
- Smythies L. E., *et al.* 2005. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. *J. Clin. Invest.* **115**: 66–75.
- Sun C. M., *et al.* 2007. Small intestine lamina propria dendritic cells promote *de novo* generation of Foxp3 T reg cells via retinoic acid. *J. Exp. Med.* **204**: 1775–85.
- Suzuki R., Kohno H., Suige S., Nakagama H., Tanaka T. 2006. Strain differences in the susceptibility to azoxymethane and dextran sodium sulfate-induced colon carcinogenesis in mice. *Carcinogenesis*. 27(1):162-9
- Stephensen C. B. 2001. Vitamin A, infection, and immune function. *Annu. Rev. Nutr.* **21**: 167–192.

- Tanaka T., et al. 2003. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. *Cancer Sci.* **94**:965–73.
- Tanaka T., Oyama T., Yasui Y. 2008. Dietary supplements and colorectal cancer. *Curr Nutraceutical Res.* 6:165-88.
- Tanaka T. 2009. Colorectal Carcinogenesis : Review Of Human And Experimental Animal Studies. *Journal of Carcinogenesis;* 8 : 5.
- Vakkila J., Lotze M.T. 2004. Inflammation and necrosis promote tumour growth. *Nature Rev Immunol.* 4: 641-648.
- de Waal Malefyt R., Haanen J., Spits H., Roncarolo M. G., te Velde A., Figdor C., et al. 1991. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. *J Exp Med.* 174: 915-24.
- Wang, Jingsong., Fathman J. W., Vilarino G. L., Scimnone L., Andrian U. H. 2006. Transcription Factor T-Bet Regulates Inflammatory Arthritis Through Its Function In Dendritic Cell. *J.Clin invest* 116:414-421.
- Yang H., Rotter J. I. 1995. Genetic aspects of idiopathic inflammatory bowel disease. In: *Inflammatory Bowel Disease*, JB Kirsner and RG Shorter (eds). Williams & Wilkins, Baltimore, Maryland, pp. 301-331.
- Yoshimura A. 2006. Signal transduction of inflammatory cytokines and tumor development. *Cancer Sci.* 97(6): 439-47.
- Zhu J., et al. 2004. Conditional deletion of Gata3 shows its essential function in TH1–TH2 responses. *Nature Immunol.* **5**, 1157–1165.